Skip to main content
Smart Investors Daily
PT

NASDAQ · PTPI

Petros Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.00

Down-$0.00 (-34.21%)

Updated Sep 20, 2026, 4:00 AM

SID Score

3.9/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
392.62K
P/E ratio
-0.08
Dividend yield
0.00%
52-week range
$0.00 – $2.62
Volume
103.63K
Avg. volume
275.54K

Price performance

PTPI price history

1M range · 0 trading sessions · Daily adjusted prices

PTPI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest PTPI news

The latest Smart Investors Daily articles mentioning PTPI.

PTPI research

Overview

Company profile and research snapshot.

Company profile

PETROS PHARM INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$1.02
Implied upside
Analysts
7
PTPI recent ratings
DateFirmRatingTarget
Dec 8, 2023Maxim GroupBuy
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Dec 3, 2025

Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)

Profitability This table compares Statera Biopharma and Petros Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Statera Biopharma N/A N/A N/A Petros Pharmaceuticals N/A -78.22% -23.50% Insider and Institutional Ownership 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 5.5% of Statera Biopharma shares

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.